FDA approves Valneva's chikungunya vaccine

The U.S. Food and Drug Administration (FDA) on Thursday approved Valneva's (VLS.PA) single-shot vaccine for individuals 18 years of age and older who are at increased risk of exposure to the chikungunya virus.

Valneva's vaccine, with the brand name Ixchiq, is the first preventive shot to be approved in the United States for the mosquito-borne disease.